A number of epigenetic therapies such as SIRT1 inhibitors, HDAC inhibitors and EZH2 inhibitors are currently in clinical trials for many cancer indications, and have shown promise in murine models and good safety profiles in Phase I healthy individuals. This evidence concerns the gene EZH2 and cancer.